Abbott Laboratories: A Timeless Investment for Steady Growth and Dividends

Why Ozempic Isn't Denmark's Greenland Bargaining Chip with the US

A Pivotal Moment: Protalix Biotherapeutics Stands on the Cusp of a Game-Changing Decision for Elfabrio

Absci's AI-Powered Drug Hunt: Unpacking the Potential of ABS-101 and ABS-201

Telangana's Bold Leap: Forging a Global Life Sciences Powerhouse by 2030

Abbott Laboratories: A Crucial Quarter on the Horizon

Structure Therapeutics CEO Charts Course for Next-Gen Obesity Treatments

Amgen's Horizon: Bradway Shares Strategic Vision with Cramer

More Than Business: Incyte's Identity Forged in the Blood Cancer Battle

The J.P. Morgan Healthcare Conference 2026: Day 2 Unpacked

Unlocking New Frontiers: How Revolution Medicines and Merck Are Redefining the Cancer Fight

The Evolving Landscape of Pharma and Biotech Employment

Navigating the Future of Wellness: A Human Look at Healthcare's Trajectory Towards 2026

Novo Nordisk's Bold Gambit: Wegovy Price Slashed by Half for China Debut

Sanofi and Dynavax: A Shrewd Shingles Deal with Unseen Upside

The Last-Minute Playbook: Unpacking 2025's Final Market Calls

Unpacking the Ambition: Trump's Most-Favored-Nation Drug Pricing Push

The Future is Oral: Why Novo Nordisk's Wegovy Pill is a Game-Changer

Bristol Myers Squibb: A Cautious Optimism Amidst Looming Headwinds

Regeneron's Remarkable Resurgence: Charting the Course of a Biotech Comeback

A Shifting Landscape: Trump, Cannabis, and the Power of the Purse

The 'Skinny Label' Showdown: How a Supreme Court Case Could Redefine Generics and Drug Prices

ASH 2025: Glimmers of Hope and Big Strides in Blood Disorders

Bengaluru Gears Up for Vital New Drug Testing Lab, Promising Faster Results and Safer Medicines

A Sweeping Review: CDC's ACIP Panel Takes a Hard Look at the Entire Childhood Vaccine Schedule

Roche's Enduring Appeal: Navigating Growth Amidst Valuation Concerns

A New Era for Public Health: CDC Panel Greenlights Universal Hepatitis B Vaccination

A New Chapter for Multiple Sclerosis Treatment: Lupin's Landmark USFDA Approval

Cramer's 2025 Check-Up: Is Merck Still a Buy?

The Buzz from the Street: Top Stocks Drawing Analyst Attention This Thursday

The Anticipation Builds: ASH 2025 and the Evolving Landscape of Blood Cancer Therapies

The FDA's Bold New Vision: Could One Clinical Trial Be Enough for Drug Approval?

A Glimmer of Hope for Hair Loss Sufferers: Cosmo Pharma's Breezula Delivers in Landmark Trial

A Notable Shift: Dr. Theresa Michele Steps Down from FDA's Nonprescription Drug Leadership

Sai Parenterals Makes a Bold Global Move, Acquires Majority Stake in Australia's Noumed

The Fight for Affordable Medicine: Hospitals Take On 340B Program Changes

Neumora Gets a Big Boost: RBC Capital Markets Sees Major Upside!

A New Prescription for Prosperity: US & UK Seal Zero-Tariff Pharma Deal

A New Dawn for Skin Cancer Patients: Citius Oncology Launches Lymphir in the US